Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$2.06
-$0.04(-2.50%)
At close: 4:00 PM EDT
$2.06
-$0.04(-2.50%)
Day’s Range― - ―
52-Week Range$1.27 - $3.56
Previous Close$1.6
Volume150.11K
Average Volume (3M)295.57K
Market Cap
$75.42M
Enterprise Value-$13.37M
Total Cash (Recent Filing)$89.96M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 12, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.88
Shares Outstanding42,853,363
10 Day Avg. Volume260,937
30 Day Avg. Volume295,574
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap-0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.31
Enterprise Value/Ebitda0.17
Forecast
1Y Price Target
$10.50Price Target Upside409.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Precision Oncology PlatformA proprietary proteomics-based platform could improve how Acrivon identifies responsive patients and prioritizes oncology candidates. If validated clinically, this precision approach may support differentiated development decisions and strengthen the company’s ability to build a focused pipeline over time.
Low LeverageVery low leverage and still-positive equity provide greater financial flexibility than a highly indebted clinical-stage peer. This reduces mandatory financing pressure from debt service and leaves more capacity to direct available resources toward clinical development and platform advancement.
Oncology PipelineAn active pipeline of investigational oncology medicines gives Acrivon multiple opportunities to generate clinical validation and future commercial value. Multiple candidates can also provide portfolio optionality, although their eventual contribution depends on successful trial outcomes and approval.
Bears Say
No Product RevenueThe absence of product revenue means Acrivon has not yet established a commercial operating engine or recurring sales base. Near-term progress therefore depends on clinical execution and external funding, while the lack of operating leverage leaves the business exposed to continued development spending.
Large Recurring LossesLarge recurring net losses indicate that the current business model consumes capital before any approved product can offset development costs. Continued losses can erode equity and increase reliance on future financing, making sustained clinical execution essential to preserve long-term financial viability.
Persistent Cash BurnPersistent negative operating and free cash flow limits Acrivon’s ability to fund its pipeline internally. Ongoing burn can accelerate balance-sheet erosion and create repeated dependence on external capital, potentially constraining development pace and strategic flexibility if financing becomes less available.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.27 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $75.42M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 25 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.502 by $0.072.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.44.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,853,363 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.502. Following the earnings report the stock price went up 7.558%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (409.71% Upside)
$10.50 (409.71% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.29%
12-Months-Change
Fundamentals
Return on Equity
-70.14%
Trailing 12-Months
Asset Growth
-37.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$10.50
▲(409.71% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.81% Insiders
2.57% Mutual Funds
34.95% Other Institutional Investors
23.86% Public Companies and
Individual Investors